膀胱癌组织中TopoⅡα和RRM1蛋白表达水平及其临床意义-东南大学学报医学版

膀胱癌组织中TopoⅡα和RRM1蛋白表达水平及其临床意义

单位：唐山市人民医院泌尿外科, 河北唐山 063000

分类号：R737.14

出版年·卷·期（页码）：2019·38·第二期（296-302）

摘要：

目的：探讨拓扑异构酶（Topo）Ⅱα和核苷酸还原酶M1亚基（RRM1）蛋白在膀胱癌组织中的表达及其临床意义。方法：本院泌尿外科确诊的膀胱癌患者98例，同期选择24例癌旁正常组织作为对照组，酶联免疫吸附法及免疫组化方法测定TopoⅡα和RRM1蛋白表达。结果：膀胱癌组织TopoⅡα、RRM1蛋白表达水平高于癌旁正常组织，差异均有统计学意义（t=12.56、16.79，P<0.05）；膀胱癌组织TOPOⅡα、RRM1阳性率高于癌旁正常组织，且差异有统计学意义（χ²=23.17、27.56，P<0.05）；TOPOⅡα、RRM1蛋白表达与年龄相关性不明显，差异均无统计学意义（χ²=1.56、1.97，P>0.05）；与病理分型、病理学分级、TNM分期、浸润深度、淋巴血管间隙浸润、淋巴结转移相关性明显，且病理学分级越高、TNM分期越高、有淋巴血管间隙浸润、有淋巴结转移，TOPOⅡα、RRM1蛋白阳性表达率越高，差异均有统计学意义（χ²=12.13、14.15、13.14、8.1、12.67、10.58、17.13、14.58、16.14、9.79、10.23，P<0.05）；不同TNM分期的TOPOⅡα、RRM1阴性组3年生存率及生存期均明显高于TOPOⅡα、RRM1阳性组，差异均有统计学意义（χ²=16.45、14.45、15.13、12.15、12.87、13.13、14.54、14.92，P<0.05）。结论：TOPOⅡα、RRM1蛋白在膀胱癌组织的表达量高于癌旁正常组织，TOPOⅡα、RRM1蛋白在膀胱癌的发生发展过程中起促进作用；TOPOⅡα、RRM1蛋白阴性表达能获得较好的预后。

Objective:To investigate the expression of topoisomerase(Topo)Ⅱα and ribonucleotide reductase subunit M1(RRM1) protein in bladder cancer and its clinical significance. Methods:98 cases of bladder cancer diagnosed in urology department of our hospital were selected, and 24 cases of the adjacent normal tissues during the same period were selected as the control group. Enzyme-linked immunosorbent assay and immunohistochemistry were used to detect the expression of TopoⅡα and RRM1 protein. Results:The expressions of TopoⅡα and RRM1 protein in bladder cancer tissues were higher than those in adjacent normal tissues (t=12.56,16.79, P<0.05); The positive rates of TOPOⅡα and RRM1 in bladder cancer tissues were significantly higher than those in adjacent normal tissues (χ²=23.17, 27.56, P<0.05); The positive expression of TOPOⅡα and RRM1 protein was positively correlated with pathological type, pathological grade, TNM stage, invasive depth lymphatic vessel space invasion and lymph node metastasis(χ²=12.13, 14.15, 13.14, 8.1, 12.67, 10.58, 17.13, 14.58, 16.14, 9.79, 10.23,P<0.05); The 3 year survival rate and survival time of TOPO Ⅱ negative and RRM1 negative TNM groups were significantly higher than those of TOPO Ⅱ, RRM1 positive group. The differences were statistically significant (χ²=16.45, 14.45, 15.13, 12.15, 12.87, 13.13, 14.54, 14.92, P<0.05). Conclusion:The expressions of TOPOⅡα and RRM1 in bladder cancer tissues are higher than those in adjacent normal tissues, suggesting that TOPOⅡα and RRM1 proteins can promote the development of bladder cancer. The positive expressions of TOPOⅡα and RRM1 protein mean a good prognosis.

参考文献：

[1] CHEN W,ZHENG R,BAADE P D,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
[2] 李绍成,骆本军,罗建蓉.TURBT联合吡柔比星灌注对浅表性膀胱癌肿瘤细胞活力及mTOR通路的影响[J].现代医学,2017,45(7):933-937.
[3] 刘涛,张璐,张凡.腹腔镜根治性膀胱全切除联合回肠原位新膀胱术对膀胱癌的疗效及尿动力学影响[J].现代医学,2017,45(5):673-677.
[4] WANG H,MEN C P.Correlation of increased expression of microRNA-155 in bladder cancer and prognosis[J].Laboratory Medicine,2015,46(2):118-119.
[5] 叶新青,蒋奕,刘鹏,等.乳腺癌蒽环类药物化疗疗效与TopoⅡα、HER-2的关系[J].诊断病理学杂志,2015,22(1):38-40.
[6] 李铁灵,郭海峰,李华洋.三阴性年轻乳腺癌患者BRCA1、TopoⅡα、Bcl-2表达和预后的关系[J].现代肿瘤医学,2016,8(2):231-233.
[7] 唐志强.乳腺癌患者C-erbB-2、P53、Ki67、TopoⅡα的表达与病理特点及预后的相关性[D].苏州:苏州大学,2016.
[8] WANG B,MENG J,WEN L.Expression of RRM1,CDX2 in carcinogenesis of gastric mucosa and their correlation[J].Journal of Changzhi Medical College,2017,7(9):89-91.
[9] MENG J,TANG Z,WEN L,et al.Clinical significance of RRM1,CDX2 expression in different gastric mucosa lesions[J].Journal of Dalian Medical University,2017,5(8):45-47.
[10] ISLAM M S,PARK S,SONG C,et al.Fluorescein hydrazones:a series of novel non-intercalative topoisomerase Ⅱα catalytic inhibitors induce G1 arrest and apoptosis in breast and colon cancer cells[J].Eur J Med Chem,2017,125(6):49-51.
[11] EMANUELLI A,BORRONI A P,APELSARID L,et al.Smurf2-mediated stabilization of DNA topoisomerase Ⅱ α controls genomic integrity[J].Cancer Research,2017,77(16):4217.
[12] KOZUKI T,CHIKAMORI K,SURLEAC M D,et al.Roles of the C-terminal domains of topoisomerase Ⅱα and topoisomerase Ⅱβ in regulation of the decatenation checkpoint[J].Nucleic Acids Res,2017,45(10):5995-6010.
[13] WINTHER T L,TORP S H.DNA topoisomerase Ⅱα and mitosin expression predict meningioma recurrence better than histopathological grade and MIB-1 after initial surgery[J].PLoS One,2017,12(3):316-317.
[14] KARELIA D N,SK U H,SINGH P,et al.Design,synthesis,and identification of a novel napthalamide-isoselenocyanate compound NISC-6 as a dual topoisomerase-Ⅱα and Akt pathway inhibitor,and evaluation of its anti-melanoma activity[J].Eur J Pharmacol,2017,6(6):135-139.
[15] CAI Y,ZHAO B,LIANG Q,et al.The selective effect of glycyrrhizin and glycyrrhetinic acid on topoisomerase Ⅱ α and apoptosis in combination with etoposide on triple negative breast cancer MDA-MB-231 cells[J].Eur J Pharmacol,2017,809(5):87-97.
[16] ZOIDIS G,SOSIC A.Indenocinnoline derivatives as G-quadruplex binders,topoisomerase Ⅱ α inhibitors and antiproliferative agents[J].Bioorg Chem,2017,25(9):2625-2634.
[17] AOYAMA T,MIYAGI Y,MURAKAWA M,et al.Clinical implications of ribonucleotide reductase subunit M1 in patients with pancreatic cancer who undergo curative resection followed by adjuvant chemotherapy with gemcitabine[J].Oncol Lett,2017,13(5):3423-3425.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录